Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTAFR | P25105 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437324 | 0.82 | PTGS2 (0.50) | HTR2AHTR2CHTR2BPTGS2ACHE | |
| SCHEMBL13402844 | 0.78 | GAA (0.41) | HTR2AHTR2CHTR2BPTGS2ACHE | |
| SCHEMBL13402248 | 0.78 | PTGS2 (0.37) | HTR2AHTR2CHTR2BPTGS2ACHE | |
| SCHEMBL20082884 | 0.77 | AOC3 (0.38) | HTR2AHTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL28127826 | 0.75 | KDM4E (0.52) | HTR2AHTR2CHTR2BPTGS2ACHE | |
| SCHEMBL28207417 | 0.74 | ACHE (0.48) | HTR2AHTR2CHTR2BCYP1A2PTGS2 | |
| SCHEMBL806463 | 0.71 | ALDH1A1 (0.42) | PTGS2CYP3A4MAPTKDM4EPOLB | |
| SCHEMBL111191 | 0.69 | HTR2A (0.69) | HTR2AHTR2CHTR2BPTGS2ACHE | |
| SCHEMBL11442618 | 0.68 | HTR2A (0.43) | HTR2AHTR2CHTR2BCYP1A2PTGS2 | |
| SCHEMBL16326683 | 0.67 | MAPT (0.40) | PTGS2CYP3A4MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800756-B1 | PEPTIDE C ALPHA-AMIDES, METHODS FOR PREPARING SAME AND USES THEREOF AS PRECURSORS OF PEPTIDE C ALPHA-THIOESTERS FOR PROTEIN SYNTHESIS | CENTRE NAT RECH SCIENT (FR) | 2018-04-25 | — | — | EP | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AstraZeneca Pharmaceuticala LP (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058070-A1 | C-TERMINAL AMIDATION OF POLYPEPTIDES | IAPP, SELENOI, SCLY | HTR2A 4756/4885HTR2C 4769/4885HTR2B 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.